Evidence map›Paper›PMID 36725319›Full record

ArticleRNA (New York, N.Y.)2023

Acyclic (

Martin Egli, Mark K Schlegel, Muthiah Manoharan

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Versatile Applications of Antisense Oligonucleotides in Modern Medicine.International journal of molecular sciences · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. The XNA alphabet.Nucleic acids research · 2025
    Review
  11. Article
  12. Small interfering RNA: From designing to therapeutic in cancer.Journal, genetic engineering & biotechnology · 2025
    Review
  13. Review
  14. Article
  15. Chemical Modifications in Nucleic Acid Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  16. Review
  17. Review
  18. Structural basis for gene silencing by siRNAs in humans.bioRxiv : the preprint server for biology · 2024
    Article
  19. Article
  20. 2'-ACS medicinal chemistry letters · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Martin EgliDepartment of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA.ORCID 0000-0003-4145-356X
Mark K SchlegelAlnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, USA.ORCID 0000-0002-0127-608X
Muthiah ManoharanAlnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, USA mmanoharan@alnylam.com.ORCID 0000-0002-7931-1172
Alnylam Pharmaceuticals (United States) · USVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycol nucleic acid (GNA) is an acyclic nucleic acid analog connected via phosphodiester bonds. Crystal structures of RNA-GNA chimeric duplexes indicated that nucleotides of the right-handed (

Indexed as

Nucleic AcidsAnimalsGlycolsHumansMiceNucleic Acid ConformationNucleotidesRNAi TherapeuticsRNA, Small InterferingGlycolsNucleic AcidsNucleotidesRNA, Small Interferingglycol nucleic acidGNAoligonucleotide therapeuticsRNAi therapeuticsRNA therapeuticssiRNAs

Identifiers

PMID36725319
PMCPMC10019370
OpenAlexW4318766823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.